Journal: bioRxiv

Article Title: Integrated Microfluidic Platform for High-Throughput Generation of Intestinal Organoids in Hydrogel Droplets

doi: 10.1101/2025.06.14.659486

Figure Lengend Snippet: a) Brightfield images of colon tumor organoids in hydrogel droplets on day 3, 6, 8 and 12 (scale bar 250 µm). b) Size development analysis of colon tumor organoids over several days, with average size highlighted above (n organoids < 110). c) Brightfield images (scale bar 250 µm) and H&E staining (scale bar 100 µm) of organoids grown in domes (1:6 dilution) or droplets. d) mIF staining of organoids in hydrogel droplets and domes (1:6 dilution) on day 12 (ECAD white, Ki67 red, SOX9 turquoise, CEACAM5 pink, scale bars 100 µm). e) Drug treatment of bioreactor grown tumor organoids. Dose-response curves to compounds FOLFOX (5-Fluorouracil,: Leucovorin:Oxaliplatin = 25:5:1, the concentration specified in the graph is based on 5-Fluorouracil), SN-38, Bortezomib, Capecitabine, quantified by fluorescence analysis of cell viability by live/dead staining (n samples = 3). Schematic was created with BioRender.com.

Article Snippet: The highest drug concentrations were chosen as follows: 1 μM Bortezomib (Tocris), 200 μM SN-38 (Tocris), 50 μM Capecitabine (Selleckchem) and the combinatorial FOLFOX with 50 μM 5-Fluorouracil (Tocris), 2 μM Oxaliplatin (Tocris), 10 μM Leucovorin (Selleckchem).

Techniques: Staining, Concentration Assay, Fluorescence

Journal: International journal of immunopathology and pharmacology

Article Title: Chemotherapy elevates cell surface PD-L1 and MHC-I expression in apoptotic gastric cancer cells.

doi: 10.1177/03946320251338662

Figure Lengend Snippet: Figure 4. Effects of FOLFOX on surface MHC-I or PD-L1 expression on AGS cells. Cells were treated with FOLFOX for 48 h. Then, cells were co-stained with annexin V and MHC-I or PD-L1 antibody. (a) Cells were gated on SSC-A versus annexin V plots. Gated cells: annexin V-positive cells. (b) Percentages of annexin V-positive cells. (c) Representative histogram showing surface PD-L1 expression. Red histogram: total cells. Purple histogram: annexin V-positive cells. (d) Quantification of relative cell surface PD-L1 intensity. (e) Representative dot plots showing the expression of annexin V and surface PD-L1 on AGS cells. (f) Quantification annexin V-positive and surface PD-L1-positive cells, and annexin V-negative and surface PD-L1-positive cells. (g) Cells were gated on SSC-A versus annexin V plots. Gated cells: annexin V-positive cells. (h) Percentages of annexin V-positive cells. (i) Representative histogram showing surface MHC-I expression. Red histogram: total cells. Purple histogram: annexin V-positive cells. (j) Quantification of relative cell surface MHC-I intensity. (k) Representative dot plots showing the expression of annexin V and surface MHC-I on AGS cells. (l) Quantification of annexin V-positive and surface MHC-I-positive cells, and annexin V-negative and surface MHC-I-positive cells. *Indicated group versus vehicle, p < 0.05.

Article Snippet: For FOLFOX treatment, cells were treated with FOLFOX (leucovorin: 14 μM; 5-Fu: 200 μM; oxaliplatin: 6 μM) for 48 h.28 Assessments of annexin V, surface PD-L1, and surface MHC-I To measure the cell surface levels of phosphatidylserine (PS), PD-L1, and MHC-I, cells were treated with IC50 of 5-Fu, Cis, and MMC or FOLFOX for 48 h. Cell surface PS, PD-L1, and MHC-I were stained by PE annexin V (BioLegend, USA), extracellular domain-specific Alexa Fluor 488-conjugated PD-L1 antibody (Cell signaling Technology, USA), and Alexa Fluor 488-conjugated MHC-I antibody (Santa Cruz, USA), respectively.29 In addition, cells were incubated with isotype control antibody, either Alexa Fluor 488-conjugated mouse IgG2 isotype control (for MHC-I) or Alexa Fluor 488-conjugated rabbit IgG isotype control (for PD-L1).

Techniques: Expressing, Staining

Journal: PLOS One

Article Title: Prognostic significance of KRAS , NRAS , BRAF , and PIK3CA mutations in stage II/III colorectal cancer: A retrospective study and meta-analysis

doi: 10.1371/journal.pone.0320783

Figure Lengend Snippet: Baseline characteristics of studies included in meta-analysis.

Article Snippet: Gavin, 2012 , NSABP C-07, C-08 , Stage II-III CC , 5FU/LV + oxaliplatin vs 5FU/LV; FOLFOX + bevacizumab vs FOLFOX , 2226/5202 (42.8) , 793 , 59 , 316 , 422 , NR , DFS, OS , No.

Techniques: Adjuvant